JPH0799986A - Cell containing lactobacillic acid in high concentration and its production - Google Patents
Cell containing lactobacillic acid in high concentration and its productionInfo
- Publication number
- JPH0799986A JPH0799986A JP5269757A JP26975793A JPH0799986A JP H0799986 A JPH0799986 A JP H0799986A JP 5269757 A JP5269757 A JP 5269757A JP 26975793 A JP26975793 A JP 26975793A JP H0799986 A JPH0799986 A JP H0799986A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- lactobacillic
- lactobacillic acid
- fat
- bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJKRDVKGCQRKBI-UHFFFAOYSA-N Lactobacillinsaeure Natural products CCCCCCC1CC1CCCCCCCCCC(O)=O IJKRDVKGCQRKBI-UHFFFAOYSA-N 0.000 title claims abstract description 64
- IJKRDVKGCQRKBI-ZWKOTPCHSA-N lactobacillic acid Chemical compound CCCCCC[C@H]1C[C@H]1CCCCCCCCCC(O)=O IJKRDVKGCQRKBI-ZWKOTPCHSA-N 0.000 title claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 26
- 241000194036 Lactococcus Species 0.000 claims abstract description 21
- 238000010521 absorption reaction Methods 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 239000003112 inhibitor Substances 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 241000194035 Lactococcus lactis Species 0.000 claims description 6
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 241000178948 Lactococcus sp. Species 0.000 claims 2
- 239000003925 fat Substances 0.000 abstract description 28
- 239000003921 oil Substances 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000003472 neutralizing effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 47
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 23
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 18
- 239000002609 medium Substances 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 10
- 235000014121 butter Nutrition 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- VHFJKUCTXWOCRX-UHFFFAOYSA-N OC(=O)CCCCCCCCC.C(CCCCC)C1CC1 Chemical compound OC(=O)CCCCCCCCC.C(CCCCC)C1CC1 VHFJKUCTXWOCRX-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、シクロプロパン環を含
む炭素数19の脂肪酸である、ラクトバチリン酸を高濃度
に含有する菌体およびその菌体の製造方法ならびに利用
方法に関するもので、さらに脂肪吸収抑制食品および脂
肪吸収抑制剤に関する。TECHNICAL FIELD The present invention relates to a bacterium containing a high-concentration lactobacillic acid, which is a C 19 fatty acid containing a cyclopropane ring, a method for producing the bacterium, and a method for using the bacterium. The present invention relates to absorption-suppressing foods and fat absorption-suppressing agents.
【0002】[0002]
【従来の技術】ラクトバチリン酸(2-hexylcyclopropane
decanoic acid)は、1954年にHofmannらによってラクト
バチルス属菌体より見いだされた細胞壁/細胞膜構成脂
質である。本脂肪酸は、炭素数が奇数であること、シク
ロプロパン環を有するため融点が33.6〜35℃と極めて低
いことを特徴とする脂肪酸である[Dictionary of Organ
ic Compounds, 5th. edit. vol.3, 2946(1982)] 。その
構造式は、化1で示される。2. Description of the Related Art Lactobacillic acid (2-hexylcyclopropane)
decanoic acid) is a cell wall / cell membrane-constituting lipid found by Hofmann et al. in 1954 from Lactobacillus cells. This fatty acid has an odd number of carbon atoms and has a cyclopropane ring and thus has a very low melting point of 33.6 to 35 ° C. [Dictionary of Organ]
ic Compounds, 5th. edit. vol.3, 2946 (1982)]. Its structural formula is shown in Chemical formula 1.
【0003】[0003]
【化1】 [Chemical 1]
【0004】これまでラクトバチルス属菌体を含め、多
くの細菌にラクトバチリン酸が含有されていることが報
告されている。ラクトコッカス属菌に含まれるラクトバ
チリン酸の含量は、全脂肪酸組成の25%程度であると報
告されている。また、Schmitt ら[Milchwissenschaft 4
4, 556 (1989)]によるとロイコノストック属の菌体に
は、全脂肪酸組成の8〜50%のラクトバチリン酸が含ま
れていることが報告されている。ラクトコッカス属菌体
に含まれるラクトバチリン酸の含量は、通常の培養条件
下では、全脂肪酸組成の25%程度であり、最高でも44%
であるとされている[Shchleifer, K. H. et al. Syste
m. Appl. Microbiol.6, 183-195 (1985)]。ラクトバチ
リン酸などのシクロプロパン環を有する脂質は吸収され
にくい脂質として知られており、ラクトバチリン酸ある
いはこれを含有する脂質、菌体等を多量に生産すること
が工業的に望まれている。It has been reported so far that many bacteria, including Lactobacillus cells, contain lactobacillic acid. It has been reported that the content of lactobacillic acid contained in Lactococcus is about 25% of the total fatty acid composition. See also Schmitt et al. [Milchwissenschaft 4
4, 556 (1989)], it has been reported that the leuconostoc cells contain lactobacillic acid in 8 to 50% of the total fatty acid composition. Under normal culture conditions, the content of lactobacillic acid contained in Lactococcus is about 25% of the total fatty acid composition, and at most 44%.
[Shchleifer, KH et al. Syste
Appl. Microbiol. 6, 183-195 (1985)]. A lipid having a cyclopropane ring such as lactobacillic acid is known as a lipid that is difficult to be absorbed, and it is industrially desired to produce a large amount of lactobacillic acid, a lipid containing the same, a bacterial cell or the like.
【0005】[0005]
【発明が解決しようとする課題】本発明は、上記のよう
に脂肪酸として特異的な生理活性を有するラクトバチリ
ン酸を多量に含有する菌体または油脂を提供することを
課題とする。また、本発明は、ラクトバチリン酸を多量
に含有する菌体または油脂の効率の良い製造方法を提供
することを課題とする。さらに、本発明は、このような
菌体あるいはラクトバチリン酸を多量に含有する、脂肪
吸収抑制飲食品あるいは医薬を提供することを課題とす
る。SUMMARY OF THE INVENTION An object of the present invention is to provide a microbial cell or fat containing a large amount of lactobacillic acid having a specific physiological activity as a fatty acid as described above. Another object of the present invention is to provide a method for efficiently producing cells or fats and oils containing a large amount of lactobacillic acid. A further object of the present invention is to provide a fat absorption-suppressing food or drink or a drug containing a large amount of such bacterial cells or lactobacillic acid.
【0006】[0006]
【課題を解決するための手段】本発明者は、ラクトコッ
カス属乳酸菌の菌体中の構成脂肪酸の検討を行っていた
ところ、ラクトコッカス属菌体を、pHを一定に制御し
た培地中で培養すると菌体中の脂肪酸含量が上昇し、菌
体自体の収量も上昇するためラクトバチリン酸の収量が
飛躍的に上昇することを見いだし、上記課題の解決に成
功した。Means for Solving the Problems The present inventor was examining the constituent fatty acids in the cells of lactic acid bacteria of the genus Lactococcus, and found that the cells of the genus Lactococcus were cultured in a medium in which the pH was controlled to be constant. Then, the fatty acid content in the bacterial cells was increased, and the yield of the bacterial cells themselves was also increased, and it was found that the yield of lactobacillic acid was dramatically increased, and the above problems were successfully solved.
【0007】本発明は、ラクトコッカス属(Lactococcu
s) に属する菌体をpH制御下で培養することにより、
ラクトバチリン酸を高濃度に含有することを特徴とする
菌体を製造する方法に関する。また、本発明は、このよ
うな菌からラクトバチリン酸を高濃度に含有する油脂を
採取することを特徴とするラクトバチリン酸含有油脂の
製造法に関する。さらに、本発明は、このように高濃度
にラクトバチリン酸を含有する菌体およびその油脂を含
有する飲食品及び医薬に関する。The present invention relates to the genus Lactococcu
By culturing cells belonging to ( s) under pH control,
The present invention relates to a method for producing bacterial cells, which comprises containing lactobacillic acid in a high concentration. The present invention also relates to a method for producing a lactobacillic acid-containing oil or fat, which comprises collecting an oil or fat containing lactobacillic acid at a high concentration from such a bacterium. Furthermore, the present invention relates to foods and drinks and pharmaceuticals containing microbial cells containing lactobacillic acid in such a high concentration and oils and fats thereof.
【0008】本発明に使用するラクトコッカス属に属す
る乳酸菌としては、ラクトコッカス属に属し[Schleife
r,K.H. et al. System. Appl. Microbiol. 6 183 (198
5)] 、ラクトバチリン酸の生産能を有する菌種であれ
ば、いずれも使用することができる。このような菌種と
しては、ラクトコッカス・ラクチス・サブスピーシーズ
・ラクチス、ラクトコッカス・ラクチス・サブスピーシ
ーズ・クレモリス等がある。しかし、特にラクトコッカ
ス・ラクチス・サブスピーシーズ・クレモリス SBT 049
5 株 (微工研菌寄第 10053号) を用いるとラクトバチリ
ン酸を菌体に高濃度に含有させることができるので好ま
しい。The lactic acid bacteria belonging to the genus Lactococcus used in the present invention belong to the genus Lactococcus [Schleife
r, KH et al. System. Appl. Microbiol. 6 183 (198
5)] Any of the bacterial species capable of producing lactobacillic acid can be used. Examples of such bacterial species include Lactococcus lactis subspecies lactis and Lactococcus lactis subspecies cremoris. But especially Lactococcus lactis subspecies cremoris SBT 049
It is preferable to use 5 strains (Microtechnology Research Institute No. 10053) because lactobacillic acid can be contained in the cells at a high concentration.
【0009】この菌株は、本発明者らによって北欧の粘
質発酵乳ヴィリーから分離されたものであって、その分
離方法及び菌学的性質は特開平3-229702号公報に記載さ
れている。この菌株は、当初、ストレプトコッカス・ク
レモリス(Streptococcus cremoris)SBT 0495(寄託番号
微工研菌寄第 10053号) として寄託されていたが、分類
の変更があり、現在はラクトコッカス・ラクチス・サブ
スピーシーズ・クレモリス(Lactococcus lactis subsp.
cremoris) SBT 0495(受託番号微工研菌寄第 10053号)
として工業技術院微生物工業技術研究所(現 生命工学
技術研究所)に寄託されている。その主な菌学的性質を
参考までに示すと次のとおりである。This strain was isolated by the present inventors from the Nordic viscous fermented milk villi, and its isolation method and mycological properties are described in JP-A-3-229702. This strain was initially deposited as Streptococcus cremoris SBT 0495 (Deposit No. Lactococcus lactis subsp.
cremoris) SBT 0495 (Accession No. Microtech Lab.
Has been deposited with the Institute of Microbial Technology, Institute of Industrial Technology (currently Institute of Biotechnology). The main mycological properties are shown below for reference.
【0010】 [0010]
【0011】次にこれらの乳酸菌によるラクトバチリン
酸高含有菌体の製造方法を示す。ラクトコッカス属乳酸
菌の培養基としては、乳培地または乳成分を含む培養
基、または、これらの成分を含まない半合成、合成の培
養基を使用することができる。このような培養基とし
て、Nakajimaら[J. Dairy Sci.73 1473 (1990)]の次の
培地を例示することができる。Next, a method for producing lactobacillic acid-rich cells using these lactic acid bacteria will be described. As the culture medium for lactic acid bacteria of the genus Lactococcus, a milk culture medium or a culture medium containing milk components, or a semi-synthetic or synthetic culture medium not containing these components can be used. As such a culture medium, the following medium of Nakajima et al. [J. Dairy Sci. 73 1473 (1990)] can be exemplified.
【0012】 ホエイ寒天培地〔グルコース10g、ガ
ラクトース10g、チーズホエイ粉(雪印乳業製)80g、
寒天15g及び蒸留水1リットルを混和し、pH6.8 に調
製した培地〕。 ホエイパーミエート培地〔10%還元脱脂乳を 115℃
で15分間加熱滅菌し、フィルター滅菌したアクチナーゼ
E(商品名)を脱脂乳1リットル当たり50mg添加し、37
℃で16時間加温し、 100℃で5分間加熱して酵素を失活
させた。この上清液を限外濾過(UF)処理(モデルSE
P-1013、旭化成製)し、得られるパーミエートを 115℃
で15分間加熱滅菌して培地とする〕。Whey agar medium [glucose 10 g, galactose 10 g, cheese whey powder (manufactured by Snow Brand Milk Products) 80 g,
A medium prepared by mixing 15 g of agar and 1 liter of distilled water to adjust the pH to 6.8]. Whey permeate medium [10% reduced skim milk at 115 ° C
After heat sterilizing for 15 minutes at 50 ° C, add 50 mg of filter-sterilized actinase E (trade name) per 1 liter of skim milk, 37
The enzyme was inactivated by heating at 0 ° C for 16 hours and heating at 100 ° C for 5 minutes. This supernatant is processed by ultrafiltration (UF) (model SE
P-1013, manufactured by Asahi Kasei) and the permeate obtained is 115 ° C.
Heat sterilize for 15 minutes to prepare the medium].
【0013】培養は、培養中に乳酸菌が生成する乳酸を
中和し、培養物のpHを乳酸菌の生育に良好な中性付近
(pH5〜8、好ましい範囲は 5.5〜6.5)になるよう、
一定に制御した中和培養によって行う。この際に使用す
る中和剤は、乳酸菌の培養に影響を与えないものであれ
ばいかなる中和剤を使用することができる。このような
中和剤としてはアンモニアが好ましいが、他には水酸化
ナトリウム、水酸化カリウム等も例示することができ
る。In the culture, the lactic acid produced by the lactic acid bacterium is neutralized, and the pH of the culture is adjusted to near neutral (pH 5 to 8, preferably 5.5 to 6.5), which is good for the growth of the lactic acid bacterium.
It is carried out by a constant controlled neutralization culture. As the neutralizing agent used at this time, any neutralizing agent can be used as long as it does not affect the culture of lactic acid bacteria. Ammonia is preferable as such a neutralizing agent, but sodium hydroxide, potassium hydroxide and the like can also be exemplified.
【0014】ラクトバチリン酸高濃度含有ラクトコッカ
ス属菌体は、そのままの状態、また乾燥した状態でも使
用することができる。ラクトバチリン酸高濃度含有菌体
から、油脂を採取する方法は、一般にラクトバチリン酸
高濃度含有菌体を乾燥して粉砕し、または破砕する。こ
れを油脂溶媒で抽出する。用いる溶媒は、通常食品や薬
品として用いても安全なもので、n−ヘキサンや2−プ
ロパノールなどがあげられる。これらの溶媒で室温下等
のあまり高くない温度下で振盪等をおこなって抽出す
る。次いで抽出した溶媒層を採取して溶媒を減圧蒸留等
で除去して、油脂を得る。Lactobacillus high concentration lactococcus cells can be used as they are or in a dried state. The method of collecting oils and fats from the lactobacillic acid high-concentration bacterial cells is generally to dry and pulverize or crush the lactobacillic acid high-concentration bacterial cells. This is extracted with a fat solvent. The solvent to be used is usually safe even when used as food or medicine, and examples thereof include n-hexane and 2-propanol. Extraction is performed by shaking with such a solvent at a temperature not too high such as room temperature. Next, the extracted solvent layer is collected and the solvent is removed by distillation under reduced pressure or the like to obtain fats and oils.
【0015】このようにして得られた油脂またはラクト
バチリン酸を各種の飲食品に添加することによって、脂
肪の吸収を抑制することができる。また、適当な方法で
これらの菌体から、ラクトバチリン酸を抽出して使用す
ることもできる。ラクトバチリン酸の測定は、菌体の凍
結乾燥物に塩酸/メタノールを添加し、100 ℃で3時間
加水分解したものをガスクロマトグラフィーで測定す
る。ラクトバチリン酸の確認には、ガスクロマトグラフ
ィーに接続した質量分析計の解析によって行うことがで
きる。By adding the oil or fat or lactobacillic acid thus obtained to various foods and drinks, absorption of fat can be suppressed. Also, lactobacillic acid can be extracted from these cells by an appropriate method and used. The lactobacillic acid is determined by adding hydrochloric acid / methanol to the lyophilized product of the cells and hydrolyzing at 100 ° C. for 3 hours, and then measuring by gas chromatography. Confirmation of lactobacillic acid can be performed by analysis of a mass spectrometer connected to gas chromatography.
【0016】これらのラクトバチリン酸高濃度含有乳酸
菌体は、飲食品の原料として添加してもよい。飲食品と
しては、どのようなものでもよい。その例としては、発
酵乳、チーズ、バター等の乳製品、ドリンクヨーグル
ト、乳酸菌飲料等の飲料、バターケーキ等の菓子やパン
類等をあげることができる。発酵乳や乳酸菌飲料への添
加は、発酵した製品に、回収した菌体を添加して調製す
ることもできる。また、菌体からラクトバチリン酸を抽
出した抽出液あるいはラクトバチリン酸自体も添加する
ことができる。さらに、この菌体自体、抽出液あるいは
ラクトバチリン酸を医薬として用いることもできる。医
薬としては菌体の乾燥物を粉末の形としたりあるいはラ
クトバチリン酸を含有する抽出液をカプセル化したりす
ることができる。これらは経口的に投与され、脂肪吸収
阻害剤として用いられる。投与量は1日成人1人当り10
0mg 〜5gを数回に分けて投与する。These lactic acid bacterium containing a high concentration of lactobacillic acid may be added as a raw material for food and drink. Any food or drink may be used. Examples thereof include fermented milk, dairy products such as cheese and butter, drinks such as drink yogurt and lactic acid bacteria beverages, confectionery such as butter cakes and breads. Addition to fermented milk or a lactic acid bacterium drink can also be carried out by adding recovered cells to a fermented product. Further, an extract obtained by extracting lactobacillic acid from cells or lactobacillic acid itself can be added. Furthermore, the cells themselves, the extract or lactobacillic acid can be used as a medicine. As the medicine, a dried product of bacterial cells can be made into a powder form or an extract containing lactobacillic acid can be encapsulated. These are orally administered and used as fat absorption inhibitors. Dosage is 10 per adult per day
Administer 0 mg to 5 g in several divided doses.
【0017】以下に発明の内容を具体的に説明する、し
かし、本発明は、この記載に限定されるものではない。The contents of the invention will be specifically described below, but the present invention is not limited to this description.
【実施例1】以下の方法によって、ラクトバチリン酸を
高濃度で含有するラクトコッカス属乳酸菌を調製した。
10%還元脱脂乳・プロナーゼ分解培地をNakajimaら
[J. Dairy Sci. 73 1473(1990)]の方法に従って生育用
培地(前記ホエイパーミエート培地)を調製した。調
製した本培地をジャーファーメンター中で滅菌し、同培
地で前培養したラクトコッカス・ラクチス・サブスピー
シース・クレモリスSBT 0495株 (微工研菌寄第 10053
号) を1%接種した。アンモニアを中和剤として用い、
培地のpHを5.5 に保持しながら30℃、24時間培養し
た。培養後、菌体を回収し、凍結乾燥後、菌体の収量、
菌体中のラクトバチリン酸含量を測定した。その結果を
表1に示した。対照として前記と同じラクトコッカス・
ラクチス・サブスピーシース・クレモリスSBT 0495株を
用い、上記と同じ培地中で培養期間中pHを調整するこ
となく、30℃で静置培養し、得られた菌体を用いた培養
期間中培地のpHは6.8 から4.5 に変化した。Example 1 A lactic acid bacterium of the genus Lactococcus containing a high concentration of lactobacillic acid was prepared by the following method.
10% reduced skim milk / pronase decomposition medium was prepared by Nakajima et al.
A growth medium (the above whey permeate medium) was prepared according to the method of [J. Dairy Sci. 73 1473 (1990)]. The prepared main culture medium was sterilized in a jar fermenter and pre-cultured in the same culture medium, Lactococcus lactis subsp. Cremoris SBT 0495 strain (Microtechnology Research Institute
No.) was inoculated at 1%. Using ammonia as a neutralizing agent,
The culture was incubated at 30 ° C. for 24 hours while keeping the pH of the medium at 5.5. After culturing, the bacterial cells are collected, and after freeze-drying, the bacterial cell yield,
The lactobacillic acid content in the cells was measured. The results are shown in Table 1. As a control, the same Lactococcus
Using Lactis subsp. Seacres cremoris SBT 0495 strain, static culture was performed at 30 ° C. in the same medium as above without adjusting the pH during the culture period, and the obtained bacterial cells were used for the culture period during the culture period. The pH changed from 6.8 to 4.5.
【0018】本方法で調製したラクトコッカス菌体より
抽出した脂質をガスクロマトグラフィー/質量分析計に
よる解析結果を図1に示した。質量分析計による解析の
結果、本脂質の脂肪酸が、シクロプロパン環を有する炭
素数19のラクトバチリン酸であることを確認した。表1
に示したように、乾燥菌体より抽出した総脂肪酸当たり
のラクトバチリン酸含量は、静置培養により調製した菌
体(対照)の場合は25.8%であるのに対し、pHを制御
して培養したところ、63.9%に上昇した。また乾燥菌体
の収量が10倍に上昇したので、培地当たりのラクトバチ
リン酸の収量は約32倍に上昇した。The analysis results of the lipid extracted from the Lactococcus cells prepared by this method by gas chromatography / mass spectrometry are shown in FIG. As a result of analysis with a mass spectrometer, it was confirmed that the fatty acid of the present lipid was lactobacillic acid having a cyclopropane ring and 19 carbon atoms. Table 1
As shown in, the lactobacillic acid content per total fatty acid extracted from the dried bacterial cells was 25.8% in the case of the bacterial cells prepared by static culture (control), while the cultivated by controlling the pH. However, it rose to 63.9%. Since the yield of dried cells increased 10 times, the yield of lactobacillic acid per medium increased 32 times.
【0019】[0019]
【表1】 ───────────────────────────────── pH制御培養 静置培養 (実施例1) (対照) ───────────────────────────────── 乾燥菌体収量 2.2g 0.2g (培地1リットル当たり) ラクトバチリン酸 63.9% 25.8% (総脂肪酸当たり) 脂質含量 12% 10% ラクトバチリン酸の収量 (培地1リットル当たり) 168.7mg 5.2mg ─────────────────────────────────[Table 1] ───────────────────────────────── pH control culture Static culture (Example 1) (control) ) ───────────────────────────────── Dry cell yield 2.2g 0.2g (per liter of medium) Lactobacillic acid 63.9% 25.8% (per total fatty acid) Lipid content 12% 10% Yield of lactobacillic acid (per liter of medium) 168.7mg 5.2mg ───────────── ────────────────────
【0020】[0020]
【実施例2】実施例1の方法で得られたラクトバチリン
酸を高濃度で含有する菌体を凍結乾燥して乾燥菌体を得
た。この菌体を10%の割合でバターに練り込み脂肪吸
収抑制発酵バターを調製した。すなわち、牛乳から公知
の方法で得られたクリーム(脂肪率40%)10kgを常法に
より殺菌し、これにラクトコッカス・ラクチス・サブス
ピーシーズ・ラクチスの脱脂乳培養物 700gを添加し、
10℃で16時間培養発酵した。この発酵クリームをチャー
ニングして発酵バター粒 4.5kgを得た。このバター粒に
上記のラクトバチリン酸を高濃度で含有する凍結乾燥菌
体 450gを添加しワーキングして脂肪吸収抑制発酵バタ
ーを得た。得られたこの発酵バターは,ジアセチル含量
が1.25ppm 、アセトアルデヒド含量が1.3ppm、乳清pH
は5.5 であり、ラクトバチリン酸を含有する良質で、発
酵風味の芳醇な脂肪吸収抑制発酵バターであった。Example 2 The microbial cells containing lactobacillic acid at a high concentration obtained by the method of Example 1 were lyophilized to obtain dried microbial cells. The cells were kneaded into butter at a ratio of 10% to prepare a fat absorption-suppressing fermented butter. That is, 10 kg of cream (40% fat rate) obtained from milk by a known method was sterilized by a conventional method, and 700 g of a skim milk culture of Lactococcus lactis subspecies lactis was added thereto,
It was cultured and fermented at 10 ° C for 16 hours. This fermented cream was cherned to obtain 4.5 kg of fermented butter grains. To the butter granules, 450 g of freeze-dried cells containing the above-mentioned lactobacillic acid at a high concentration was added and worked to obtain a fermented butter for suppressing fat absorption. The fermented butter obtained had a diacetyl content of 1.25 ppm, an acetaldehyde content of 1.3 ppm, and a whey pH.
Was 5.5, and it was a fermented butter containing lactobacillic acid, which was of good quality and had a rich fermented flavor and suppressed fat absorption.
【0021】[0021]
【実施例3】実施例1で得られたラクトバチリン酸高含
有ラクトコッカス菌体をラットに与えて血清中のトリグ
リセライドの含量を測定した。ラットに与えた飼料は以
下の組成のものである。Example 3 Lactococcus cells having a high content of lactobacillic acid obtained in Example 1 were fed to rats to measure the triglyceride content in serum. The feed given to the rats has the following composition.
【0022】[0022]
【表2】 ───────────────────────────────── 飼料A 飼料B ────────────────────────────────── カゼイン 20 20 ラード 10 10 コーン油 10 10 ビタミンミックス 0.85 0.85 AIN76(商品名) 塩類ミックス 4 4 AIN76(商品名) セルロース 3 3 塩化コリン 0.2 0.2 コール酸ナトリウム 0.125 0.125 シュークロース 51.825 41.825 菌体 0 10 ─────────────────────────────────[Table 2] ───────────────────────────────── Feed A Feed B ────────── ───────────────────────── Casein 20 20 Lard 10 10 Corn oil 10 10 Vitamin mix 0.85 0.85 AIN76 (trade name) Salt mix 4 4 AIN76 (trade name) Cellulose 3 3 Choline chloride 0.2 0.2 Sodium cholate 0.125 0.125 Sucrose 51.825 41.825 Bacteria 0 10 ──────────── ──────────────────────
【0023】上記の飼料を1群6匹のF−244 系ラット
(12週令、雄)に1週間摂取させた。6時間の絶食の
後、血清中のトリグリセライド量をトリグリセライド測
定キット(協和メディックス製)により測定した。The above-mentioned feed was fed to 6 F-244 rats (12 weeks old, male) per group for 1 week. After fasting for 6 hours, the amount of triglyceride in serum was measured with a triglyceride measurement kit (manufactured by Kyowa Medix).
【0024】上記飼料投与中の飼料摂取量は両群の間で
差は見られなかった。血清中のトリグリセライド量を表
3に示した。表中の値は平均値±標準偏差を示す。No difference was observed in the feed intake between the two groups during the above-mentioned feed administration. Table 3 shows the amount of triglyceride in serum. The values in the table show the average value ± standard deviation.
【0025】[0025]
【表3】 (検体数=各6) ──────────────────────── 飼料A 飼料B ──────────────────────── 102±19mg/dl 82±11mg/dl ────────────────────────[Table 3] (Number of samples = 6 each) ──────────────────────── Feed A Feed B ──────────── ───────────── 102 ± 19mg / dl 82 ± 11mg / dl ────────────────────────
【0026】上表の血清中のトリグリセライド含量を統
計的に検定したところ、危険率5%で、飼料B群に有意
の差があることが判明した。この結果、ラクトバチリン
酸高含有ラクトコッカス菌体の投与効果が認められた。
結果にしめしたように、ラクトバチリン酸を高濃度で含
有する菌体を摂取したラットの血清中のトリグリセライ
ド含量が低下していた。この結果から、ラクトバチリン
酸を高濃度で含有するラクトコッカス菌体が血中への脂
質取り込みを抑制することが明らかになった。When the triglyceride content in the serum in the above table was statistically tested, it was found that the risk rate was 5% and there was a significant difference between the feed group B. As a result, the effect of administration of Lactobacillus-rich Lactococcus cells was confirmed.
As shown in the results, the triglyceride content in the serum of rats fed with the cells containing lactobacillic acid at a high concentration was low. From these results, it was revealed that Lactococcus cells containing lactobacillic acid at a high concentration suppress the lipid uptake into blood.
【0027】[0027]
【実施例4】実施例1の方法で得られた、ラクトバチリ
ン酸高含有菌体1gを乳糖5gと混合し、顆粒状に成形
して、ラクトバチリン酸を有効成分とする脂肪吸収抑制
剤を調製した。Example 4 1 g of lactobacillic acid-rich cells obtained by the method of Example 1 was mixed with 5 g of lactose and molded into granules to prepare a fat absorption inhibitor containing lactobacillic acid as an active ingredient. .
【0028】[0028]
【実施例5】培養培地のpHを中性付近に制御して培養し
て得られた実施例1のラクトバチリン酸高濃度含有菌体
の乾燥物を超音波破砕した。得られた 100gの破砕菌体
に1リットルのn−ヘキサンを添加し、室温下で振盪し
ながら充分に抽出した。次いで、抽出した溶媒層を減圧
蒸留して溶媒を除去した。油脂11.9gが得られた。この
油脂の脂肪酸を定量したところ、7.56gのラクトバチリ
ン酸を含有していることがわかり、これが高濃度である
ことを確認した。[Example 5] The dried product of the cells containing a high concentration of lactobacillic acid of Example 1 obtained by culturing while controlling the pH of the culture medium to near neutral was sonicated. 1 liter of n-hexane was added to 100 g of the obtained disrupted cells, and the mixture was sufficiently extracted at room temperature with shaking. Then, the extracted solvent layer was distilled under reduced pressure to remove the solvent. 11.9 g of oil and fat was obtained. When the fatty acid of this oil was quantified, it was found that it contained 7.56 g of lactobacillic acid, and it was confirmed that this was a high concentration.
【0029】[0029]
【発明の効果】Wood & Reiser[J. Am, Oil Chem, Soci.
42 315 (1965)] の報告によるシクロプロパン環を有す
る脂質をラットに投与したところ、脂肪組織中でシクロ
プロパン環を有する脂肪酸が検出され、脂肪酸の吸収系
であるβ酸化系の酵素がシクロプロパン環の位置で阻害
されていることが明らかになった。このことから、ラク
イトバチリン酸も容易にβ酸化系酵素を阻害することが
推察される。つまり、ラクトバチリン酸は、吸収されに
くい脂肪酸として、脂肪吸収抑制飲食品の原料になるこ
とが期待される。また、ラクトバチリン酸を高含量で含
むラクトコッカス属菌体も、脂肪の吸収が抑制され、脂
肪吸収抑制飲食品として使用することが出来る。EFFECT OF THE INVENTION Wood & Reiser [J. Am, Oil Chem, Soci.
42 315 (1965)], when a lipid having a cyclopropane ring was administered to rats, a fatty acid having a cyclopropane ring was detected in adipose tissue, and the β-oxidation enzyme, which is a fatty acid absorption system, was detected by cyclopropane. It was revealed that it was blocked at the ring position. This suggests that lacitobacillic acid also readily inhibits β-oxidation enzymes. That is, lactobacillic acid is expected to be a raw material for fat absorption-suppressing food and drink, as a fatty acid that is difficult to be absorbed. In addition, a Lactococcus bacterium containing a high content of lactobacillic acid can also be used as a fat absorption-suppressing food or drink because fat absorption is suppressed.
【図1】本発明の方法で調製したラクトコッカス菌体抽
出脂質のガスクロマトグラフィ/質量分析計による分析
結果を示す。FIG. 1 shows the results of analysis by a gas chromatography / mass spectrometer of lipids extracted from Lactococcus cells prepared by the method of the present invention.
─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成5年11月11日[Submission date] November 11, 1993
【手続補正1】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】0029[Name of item to be corrected] 0029
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【0029】[0029]
【発明の効果】Wood&Reiser[J.Am,O
il Chem,Soci.42 315(196
5)]の報告によるシクロプロパン環を有する脂質をラ
ットに投与したところ、脂肪組織中でシクロプロパン環
を有する脂肪酸が検出され、脂肪酸の吸収系であるβ酸
化系の酵素がシクロプロパン環の位置で阻害されている
ことが明らかになった。このことから、ラクトバチリン
酸も容易にβ酸化系酵素を阻害することが推察される。
つまり、ラクトバチリン酸は、吸収されにくい脂肪酸と
して、脂肪吸収抑制飲食品の原料になることが期待され
る。また、ラクトバチリン酸を高含量で含むラクトコッ
カス属菌体も、脂肪の吸収が抑制され、脂肪吸収抑制飲
食品として使用することが出来る。EFFECT OF THE INVENTION Wood & Reiser [J. Am, O
il Chem, Soci. 42 315 (196
5)] was administered to rats, a fatty acid having a cyclopropane ring was detected in the adipose tissue, and the β-oxidation enzyme, which is a fatty acid absorption system, was located at the position of the cyclopropane ring. It became clear that it was blocked by. Therefore, it is inferred that the La transfected Bachirin acid inhibits easily β oxidative enzyme.
That is, lactobacillic acid is expected to be a raw material for fat absorption-suppressing food and drink, as a fatty acid that is difficult to be absorbed. In addition, a Lactococcus bacterium containing a high content of lactobacillic acid can also be used as a fat absorption-suppressing food or drink because fat absorption is suppressed.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(C12P 7/64 C12R 1:01) (C12N 1/20 C12R 1:01) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display area // (C12P 7/64 C12R 1:01) (C12N 1/20 C12R 1:01)
Claims (6)
した培地中で培養し、ラクトバチリン酸を高濃度で含有
するラクトコッカス属(Lactococcus sp.) に属する菌
体。1. A bacterium belonging to the genus Lactococcus (Lactococcus sp.), Which is cultivated in a medium controlled to have a constant pH around neutral during the culturing period and contains lactobacillic acid at a high concentration.
属し、ラクトバチリン酸生産能を有する菌体を、pHを
中性付近の一定に制御された培地中で培養して菌体中に
ラクトバチリン酸を高濃度に蓄積させ、この菌体を採取
することを特徴とするラクトバチリン酸を高濃度で含有
する菌体の製造法。2. A bacterium belonging to the genus Lactococcus sp. And having the ability to produce lactobacillic acid is cultivated in a medium in which the pH is controlled to be around neutral and the lactobacillic acid is contained in the bacterium. A method for producing a bacterium containing a high concentration of lactobacillic acid, which comprises collecting the bacterium in a high concentration.
ブスピーシーズ・クレモリス SBT 0495 株(微工研菌寄
第 10053号) である請求項2記載の製造法。3. The method according to claim 2, wherein the bacterial cell is Lactococcus lactis subspecies cremoris SBT 0495 strain (Ministry of Industrial Science and Technology No. 10053).
トバチリン酸含有油脂を採取することを特徴とするラク
トバチリン酸含有油脂の製造法。4. A method for producing a lactobacillic acid-containing oil or fat, which comprises collecting the lactobacillic acid-containing oil or fat from the bacterium obtained according to claim 2.
れから得られるラクトバチリン酸含有油脂を含有せしめ
たことを特徴とする脂肪吸収抑制飲食品。5. A fat absorption-suppressing food or drink containing the microbial cell obtained according to claim 1 or a lactobacillic acid-containing oil or fat obtained therefrom.
れから得られるラクトバチリン酸含有油脂を有効成分と
する脂肪吸収抑制剤。6. A fat absorption inhibitor containing the bacterium obtained according to claim 1 or a lactobacillic acid-containing oil or fat obtained therefrom as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5269757A JPH0799986A (en) | 1993-09-30 | 1993-09-30 | Cell containing lactobacillic acid in high concentration and its production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5269757A JPH0799986A (en) | 1993-09-30 | 1993-09-30 | Cell containing lactobacillic acid in high concentration and its production |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0799986A true JPH0799986A (en) | 1995-04-18 |
Family
ID=17476731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5269757A Pending JPH0799986A (en) | 1993-09-30 | 1993-09-30 | Cell containing lactobacillic acid in high concentration and its production |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0799986A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005154387A (en) * | 2003-11-28 | 2005-06-16 | National Institute Of Agrobiological Sciences | Lactobacilli inducing immunomodulative function or component thereof and method for obtaining the same |
JP2008214253A (en) * | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | Visceral fat reduction agent |
-
1993
- 1993-09-30 JP JP5269757A patent/JPH0799986A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005154387A (en) * | 2003-11-28 | 2005-06-16 | National Institute Of Agrobiological Sciences | Lactobacilli inducing immunomodulative function or component thereof and method for obtaining the same |
JP4589618B2 (en) * | 2003-11-28 | 2010-12-01 | 独立行政法人農業生物資源研究所 | Lactic acid bacteria and their components inducing immunoregulatory functions |
JP2008214253A (en) * | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | Visceral fat reduction agent |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3222157B1 (en) | Food composition, containing lactococcus strain as active ingredient, for alleviating hangover | |
JP7179343B2 (en) | Novel lactic acid strain and immunostimulant containing the same | |
AU2011300738B2 (en) | Lactococcus lactis strain with high vitamin K2 production | |
RU2687346C1 (en) | Obtaining of expressed fermented milk products | |
WO2008001497A1 (en) | Enhancer of proliferation of lactic acid bacterium, and agent for improvement in survivability of lactic acid bacterium | |
US8673616B2 (en) | Lactococcus lactis strain with high vitamin K2 production | |
KR101746227B1 (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
JP6762855B2 (en) | Muscle breakdown inhibitor | |
JP4688457B2 (en) | Immune enhancing composition | |
KR101723959B1 (en) | Food composition for relieving hangover comprising Lactococcus raffinolactis | |
JPH0799986A (en) | Cell containing lactobacillic acid in high concentration and its production | |
JPH07155103A (en) | Method for producing lactic bacteria fermentation solution | |
EP1669458B1 (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
KR101639393B1 (en) | Food composition for relieving hangover comprising Lactococcus lactis subsp. lactis | |
JP6968540B2 (en) | Oral composition | |
KR101718590B1 (en) | Food composition for relieving hangover comprising Lactococcus fujiensis | |
KR101670555B1 (en) | Food composition for relieving hangover comprising Lactococcus chungangensis | |
JP3993322B2 (en) | Lactic acid bacteria growth promoter and use thereof | |
JP2005323596A (en) | Method for producing vitamin k by culture of unnan sl-001 strain | |
KR101693945B1 (en) | Food composition for relieving hangover comprising Lactococcus lactis subsp. cremoris | |
WO2018034279A1 (en) | Composition for controlling acquired immune function suppression due to anti-influenza drug, and production method for same | |
JP2022079857A (en) | DPP-4 inhibitory composition |